Its transcriptional product, glutamine synthetase (GS) expression, is a reliable biomarker of the β-catenin mutation, while GS expression in human HCC is not always associated with β-catenin mutation (24–26). The gene discussed is GLUL; the disease is hepatocellular carcinoma.